GET THE LATEST UPDATES
Receive the latest event information about key speakers, sponsorship opportunities and exhibiting.
November 9-11, 2020 | Virtual Conference
Dr. Lynne Ensor is a Vice President, Technical, for Parexel International since August 2019. As a 21-year veteran of the U. S. Food and Drug Administration (FDA), her areas of expertise include biopharmaceutical sterile product manufacturing and testing (CMC and cGMP), risk assessment and mitigation strategies, data integrity assessment, regulatory policy and guidance development, and remediation strategies for product and facility challenges (e.g., resolving consent decrees, warning letters, 483s, and drug shortages). While serving as the Deputy Director (Acting) in the Office of Process and Facilities (OPF) within FDA/Center for Drug Evaluation and Research’s (CDER) Office of Pharmaceutical Quality (OPQ), she was responsible for new, generic and biologic drug product quality review and facility assessment. Dr. Ensor’s previous FDA positions included serving as the Director of the OPF’s Division of Microbiology Assessment, Director of the Office of Pharmaceutical Science’s New and Generic Drug Product Quality Microbiology staff, Director of the Office of Generic Drugs’ Division of Microbiology and as a CDER master CMC reviewer. In addition to Dr. Ensor’s regulatory experience, Lynne was employed at Roche Biomedical Laboratories, served as a post-doctoral research fellow at the University of Maryland at Baltimore’s School of Medicine, and served as a script consultant for the Discovery Channel. She earned her B.S. in Biology and Ph.D. in Microbiology from the University of Maryland, College Park.